NCT02842359.

Methods	Randomised, open‐label, parallel‐assignment trial
Participants	Aged ≥ 19 years to < 75 years No medication history of hyperlipidaemia and hypertension within 3 months following registration, among people with type 2 diabetes diagnosed with hyperlipidaemia and stage I hypertension (systolic blood pressure: ≥ 140 mmHg, ≤ 159 mmHg or diastolic blood pressure: ≥ 90 mmHg, ≤ 99 mmHg), with adequately controlled haemoglobin levels Diagnosis of diabetes: haemoglobin A1c ≥ 6.5% or; fasting plasma glucose level above 8 hour ≥ 126 mg/dL or plasma glucose ≥ 200 mg/dL ( 11.1 mmol/l) 2 h after a 75 g glucose load or symptoms (such as polyuria, polydipsia, unexplained weight loss) and a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L)
Interventions	Irbesartan/atorvastatin fixed‐dose combination: pharmaceutical form: tablet; route of administration: oral; other name: Rovelito Comparators Irbesartan SR47436: pharmaceutical form: tablet; route of administration: oral; other name: Aprovel Atorvastatin: pharmaceutical form: tablet; route of administration: oral; other name: Newvast
Outcomes	Primary outcomes: (time frame: 4 weeks‐maximum 5 weeks) Change from baseline in flow mediated dilatation Secondary outcomes: (Time frame: 4 weeks up to maximum 5 weeks) Rate of change from baseline in nytrotyrosine marker Rate of change from baseline in Intercellular Adhesion Molecule‐1 Rate of change from baseline in interleukin‐6 Rate of change from baseline in C‐reactive protein Change from baseline in blood pressure (irbesartan/atorvastatin fixed‐dose combination group and irbesartan group) Change from baseline in low density lipoprotein‐C (irbesartan/atorvastatin fixed‐dose combination group and atorvastatin group) Change from baseline in total cholesterol (irbesartan/atorvastatin fixed‐dose combination group and atorvastatin group) Change from baseline in high density lipoprotein‐C (irbesartan/atorvastatin fixed‐dose combination group and atorvastatin group) Change from baseline in triglycerides (irbesartan/atorvastatin fixed‐dose combination group and atorvastatin group) Change from baseline in apolipoprotein‐A1 (irbesartan/atorvastatin fixed‐dose combination group and atorvastatin group) Change from baseline in apolipoprotein‐B (irbesartan/atorvastatin fixed‐dose combination group and atorvastatin group) ‐Percentage of participants with decreased level of blood pressure (irbesartan/atorvastatin fixed‐dose combination group and irbesartan group)] Rate of change from baseline in immunosenescence T cell fractionation Rate of change from baseline in T‐cell induced inflammatory factors
Notes